With full bow strength and practical efforts to strive for spring. On January 20, at the intersection of review and expectation, Jiuzhou Pharmaceutical held its 2024 annual work meeting. Leaders from Zhongbei Jiuzhou Group, Jiuzhou Pharmaceutical, and other companies, heads of various business sectors, divisions, functional departments, general managers of subsidiaries, and middle-level and above management personnel attended the annual meeting. The meeting was held in a "live + video" format, with the main venue in Taizhou and sub-venues in various domestic and overseas subsidiaries.

The meeting focused on the theme of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," summarizing and reviewing the company's operational management work in 2024, deeply analyzing problem areas, formulating work goals and key measures for 2025, clarifying the direction of efforts, further promoting the implementation of the company's strategy, and ensuring the achievement of annual goals.

President Mei Yi will present the company's 2024 work report, coordinating the deployment of work for 2025; heads of various business lines and functional departments will report on the operational management work for 2024 and implement the action plan for 2025.

At the meeting, President Mei Yi will sign the 2025 target responsibility letter with the production platform and heads of various business sectors and divisions, signing the "military order" to sound the charge for "striving for spring" and "catching up with spring," igniting passion and striving forward.

In 2024, the complex and changing external environment and increasingly competitive industry situation pose many challenges to enterprise development. Jiuzhou people are making every effort to expand the market and increase orders, solidify the main business, respond to customer needs, and assist in the new drug listing process, achieving results that are hard-won.

The quality system operates steadily, with nearly 40 important official audits passed 100% throughout the year, winning numerous victories in customs clearance, assisting products to be listed quickly; the peptide business has gained recognition from domestic and foreign customers, with self-developed formulations such as Glimepiride and Sitagliptin successfully listed, and Sitagliptin Metformin Tablets (II) selected in the tenth batch of national procurement; assisting strategic partners in obtaining approval for hypertension treatment drugs, anti-tumor drugs approved for listing in the United States, and antibacterial drugs passing the consistency evaluation of generic drug quality and efficacy domestically. The Jiuzhou Pharmaceutical (Taizhou) production base has begun to be put into use, and the Japanese laboratory has been put into operation.

Jiuzhou Pharmaceutical has been awarded honors such as one of the top 100 pharmaceutical companies in China, one of the top 20 CXO companies, a leading enterprise in the biopharmaceutical industry in Zhejiang Province, an eagle enterprise in Zhejiang Province, and a benchmark for manufacturing quality in Zhejiang Province. It has joined the United Nations Global Compact, been selected for the "FTSE Social Responsibility Index Series," applied to join the "Science Based Targets Initiative," and is committed to green low-carbon development, co-creating a sustainable future.

Looking back at 2024, Jiuzhou people have cultivated the soil of innovation with wisdom and sweat, rooting strategic development, promoting the listing of more new drugs, and supporting more patients' hopes.

Do not waste the spring light, rise and act. In 2025, Jiuzhou Pharmaceutical will uphold the service concept of "customer first, win-win cooperation," provide better products and services for global partners, look forward to more innovations emerging, and bring more good new drugs to global patients as soon as possible to meet unmet medical needs.

President Mei Yi will point out that in the new year, the company will increase the expansion of innovative drug CDMO overseas business; the sales of raw material drug business will return to a growth track; the peptide business will continue to make efforts; promote the reform of research and development management model, improve research and development output efficiency and cost competitiveness; explore new models to enhance production operation management capabilities; improve inventory management to effectively reduce company inventory; systematically enhance enterprise management level, promote information construction, and ensure the operation and sustainable development of the enterprise.

In 2025, embrace change and traverse cycles. Chairman Hua Lirong emphasized that all Jiuzhou people should follow the annual business philosophy of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," focus on the main business, accelerate the industrialization of new businesses such as peptides; promote lean management, solidify quality and safety bottom lines, respond to the uncertain external environment, and safeguard the healthy operation of the enterprise; accelerate the reconstruction of the marketing management system, activate the "spring water" of market development; accelerate the process of globalization layout, continuously solidify core competitiveness, and strive towards the vision of "becoming a life and health enterprise for global drug innovation solutions" in the new year!

The train heading towards "spring" has already started.

Jiuzhou people embark on a new journey in 2025.

Turn around immediately and move forward without hesitation!

With full bow strength and practical efforts to strive for spring. On January 20, at the intersection of review and expectation, Jiuzhou Pharmaceutical held its 2024 annual work meeting. Leaders from Zhongbei Jiuzhou Group, Jiuzhou Pharmaceutical, and other companies, heads of various business sectors, divisions, functional departments, general managers of subsidiaries, and middle-level and above management personnel attended the annual meeting. The meeting was held in a "live + video" format, with the main venue in Taizhou and sub-venues in various domestic and overseas subsidiaries.

The meeting focused on the theme of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," summarizing and reviewing the company's operational management work in 2024, deeply analyzing problem areas, formulating work goals and key measures for 2025, clarifying the direction of efforts, further promoting the implementation of the company's strategy, and ensuring the achievement of annual goals.

President Mei Yi will present the company's 2024 work report, coordinating the deployment of work for 2025; heads of various business lines and functional departments will report on the operational management work for 2024 and implement the action plan for 2025.

At the meeting, President Mei Yi will sign the 2025 target responsibility letter with the production platform and heads of various business sectors and divisions, signing the "military order" to sound the charge for "striving for spring" and "catching up with spring," igniting passion and striving forward.

In 2024, the complex and changing external environment and increasingly competitive industry situation pose many challenges to enterprise development. Jiuzhou people are making every effort to expand the market and increase orders, solidify the main business, respond to customer needs, and assist in the new drug listing process, achieving results that are hard-won.

The quality system operates steadily, with nearly 40 important official audits passed 100% throughout the year, winning numerous victories in customs clearance, assisting products to be listed quickly; the peptide business has gained recognition from domestic and foreign customers, with self-developed formulations such as Glimepiride and Sitagliptin successfully listed, and Sitagliptin Metformin Tablets (II) selected in the tenth batch of national procurement; assisting strategic partners in obtaining approval for hypertension treatment drugs, anti-tumor drugs approved for listing in the United States, and antibacterial drugs passing the consistency evaluation of generic drug quality and efficacy domestically. The Jiuzhou Pharmaceutical (Taizhou) production base has begun to be put into use, and the Japanese laboratory has been put into operation.

Jiuzhou Pharmaceutical has been awarded honors such as one of the top 100 pharmaceutical companies in China, one of the top 20 CXO companies, a leading enterprise in the biopharmaceutical industry in Zhejiang Province, an eagle enterprise in Zhejiang Province, and a benchmark for manufacturing quality in Zhejiang Province. It has joined the United Nations Global Compact, been selected for the "FTSE Social Responsibility Index Series," applied to join the "Science Based Targets Initiative," and is committed to green low-carbon development, co-creating a sustainable future.

Looking back at 2024, Jiuzhou people have cultivated the soil of innovation with wisdom and sweat, rooting strategic development, promoting the listing of more new drugs, and supporting more patients' hopes.

Do not waste the spring light, rise and act. In 2025, Jiuzhou Pharmaceutical will uphold the service concept of "customer first, win-win cooperation," provide better products and services for global partners, look forward to more innovations emerging, and bring more good new drugs to global patients as soon as possible to meet unmet medical needs.

President Mei Yi will point out that in the new year, the company will increase the expansion of innovative drug CDMO overseas business; the sales of raw material drug business will return to a growth track; the peptide business will continue to make efforts; promote the reform of research and development management model, improve research and development output efficiency and cost competitiveness; explore new models to enhance production operation management capabilities; improve inventory management to effectively reduce company inventory; systematically enhance enterprise management level, promote information construction, and ensure the operation and sustainable development of the enterprise.

In 2025, embrace change and traverse cycles. Chairman Hua Lirong emphasized that all Jiuzhou people should follow the annual business philosophy of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," focus on the main business, accelerate the industrialization of new businesses such as peptides; promote lean management, solidify quality and safety bottom lines, respond to the uncertain external environment, and safeguard the healthy operation of the enterprise; accelerate the reconstruction of the marketing management system, activate the "spring water" of market development; accelerate the process of globalization layout, continuously solidify core competitiveness, and strive towards the vision of "becoming a life and health enterprise for global drug innovation solutions" in the new year!

The train heading towards "spring" has already started.

Jiuzhou people embark on a new journey in 2025.

Turn around immediately and move forward without hesitation!

With full bow strength and practical efforts to strive for spring. On January 20, at the intersection of review and expectation, Jiuzhou Pharmaceutical held its 2024 annual work meeting. Leaders from Zhongbei Jiuzhou Group, Jiuzhou Pharmaceutical, and other companies, heads of various business sectors, divisions, functional departments, general managers of subsidiaries, and middle-level and above management personnel attended the annual meeting. The meeting was held in a "live + video" format, with the main venue in Taizhou and sub-venues in various domestic and overseas subsidiaries.

The meeting focused on the theme of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," summarizing and reviewing the company's operational management work in 2024, deeply analyzing problem areas, formulating work goals and key measures for 2025, clarifying the direction of efforts, further promoting the implementation of the company's strategy, and ensuring the achievement of annual goals.

President Mei Yi will present the company's 2024 work report, coordinating the deployment of work for 2025; heads of various business lines and functional departments will report on the operational management work for 2024 and implement the action plan for 2025.

At the meeting, President Mei Yi will sign the 2025 target responsibility letter with the production platform and heads of various business sectors and divisions, signing the "military order" to sound the charge for "striving for spring" and "catching up with spring," igniting passion and striving forward.

In 2024, the complex and changing external environment and increasingly competitive industry situation pose many challenges to enterprise development. Jiuzhou people are making every effort to expand the market and increase orders, solidify the main business, respond to customer needs, and assist in the new drug listing process, achieving results that are hard-won.

The quality system operates steadily, with nearly 40 important official audits passed 100% throughout the year, winning numerous victories in customs clearance, assisting products to be listed quickly; the peptide business has gained recognition from domestic and foreign customers, with self-developed formulations such as Glimepiride and Sitagliptin successfully listed, and Sitagliptin Metformin Tablets (II) selected in the tenth batch of national procurement; assisting strategic partners in obtaining approval for hypertension treatment drugs, anti-tumor drugs approved for listing in the United States, and antibacterial drugs passing the consistency evaluation of generic drug quality and efficacy domestically. The Jiuzhou Pharmaceutical (Taizhou) production base has begun to be put into use, and the Japanese laboratory has been put into operation.

Jiuzhou Pharmaceutical has been awarded honors such as one of the top 100 pharmaceutical companies in China, one of the top 20 CXO companies, a leading enterprise in the biopharmaceutical industry in Zhejiang Province, an eagle enterprise in Zhejiang Province, and a benchmark for manufacturing quality in Zhejiang Province. It has joined the United Nations Global Compact, been selected for the "FTSE Social Responsibility Index Series," applied to join the "Science Based Targets Initiative," and is committed to green low-carbon development, co-creating a sustainable future.

Looking back at 2024, Jiuzhou people have cultivated the soil of innovation with wisdom and sweat, rooting strategic development, promoting the listing of more new drugs, and supporting more patients' hopes.

Do not waste the spring light, rise and act. In 2025, Jiuzhou Pharmaceutical will uphold the service concept of "customer first, win-win cooperation," provide better products and services for global partners, look forward to more innovations emerging, and bring more good new drugs to global patients as soon as possible to meet unmet medical needs.

President Mei Yi will point out that in the new year, the company will increase the expansion of innovative drug CDMO overseas business; the sales of raw material drug business will return to a growth track; the peptide business will continue to make efforts; promote the reform of research and development management model, improve research and development output efficiency and cost competitiveness; explore new models to enhance production operation management capabilities; improve inventory management to effectively reduce company inventory; systematically enhance enterprise management level, promote information construction, and ensure the operation and sustainable development of the enterprise.

In 2025, embrace change and traverse cycles. Chairman Hua Lirong emphasized that all Jiuzhou people should follow the annual business philosophy of "expanding business, addressing shortcomings, strengthening management, and increasing efficiency," focus on the main business, accelerate the industrialization of new businesses such as peptides; promote lean management, solidify quality and safety bottom lines, respond to the uncertain external environment, and safeguard the healthy operation of the enterprise; accelerate the reconstruction of the marketing management system, activate the "spring water" of market development; accelerate the process of globalization layout, continuously solidify core competitiveness, and strive towards the vision of "becoming a life and health enterprise for global drug innovation solutions" in the new year!

The train heading towards "spring" has already started.

Jiuzhou people embark on a new journey in 2025.

Turn around immediately and move forward without hesitation!